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A B S T R A C T
Background: Lutein (LT) is a naturally occurring xanthophyll carotenoid most predominant in the central ner-
vous system (CNS), but its neurotrophic role is still debated. We therefore investigated whether cord blood
concentrations correlated with a well-established neurobiomarker, namely activin A.
Methods: We conducted a prospective study on the distribution of LT and activin A in arterial cord blood of
healthy preterm (n = 50) and term (n = 82) newborns according to weeks of gestational age (wGA) and gender.
Results: LT and activin A showed a pattern of concentration characterized by higher levels (P < 0.01, for all) at
33–36 wGA followed by a progressive decrease (P < 0.01, for all) from 37 onwards with a dip at term. Both LT
and activin A were gender-dependent with signiﬁcantly (P < 0.01, for all) higher levels in all recruited females
and after sub-grouping for preterm and term births. LT (R = 0.33; P < 0.001) correlated with wGA at sampling.
There were signiﬁcant positive correlations between lutein and activin A in male (R = 0.93; P < 0.001) and
female (R = 0.89; P < 0.001) groups.
Conclusions: The present data showing a correlation between LT and activin A support the notion of a neuro-
trophic role gender-dependent for LT and open the way to further investigations correlating LT with well-es-
tablished biochemical markers of CNS development/damage.
1. Introduction
Lutein (LT) is a naturally occurring xanthophyll carotenoid, not
synthesized by humans, found in fruits and vegetables such as spinach
and kale, which are the most abundant sources in nature [1]. Both in
humans and in animals, LT concentration in the body is dependent to its
dietary intake [2]. Although the several functions of LT are still a matter
of debate, it has been shown in adults to protect skin from UV exposure,
to moderate atherosclerosis progression and to decrease the risk of
some cancer types [3–5]. In the perinatal period, LT is one of the pre-
valent carotenoids in mature breast milk [6,7]. LT and its isomer
zeaxanthin are the only carotenoids that make up the yellow pigment of
the macula, thus supporting the latter's crucial role in the protection
from oxidative damage and the occurrence of retinopathies in pre-
mature infants [8,9]. In this regard, LT supplementation associated with
lycopene and beta-carotene, in preterm newborns, has been shown to
improve neuro-retinal health [8]. LT is also the predominant carotenoid
in the central nervous system (CNS) [9,10], where it is highly con-
centrated in the frontal and occipital cortex and hippocampus areas,
which are important for learning and memory [10]. These brain LT-
speciﬁc relationships with metabolic, energy, neurotransmission and
antioxidant pathways have shown that LT may be involved in CNS
development [9,10]. A trophic role of LT in the third trimester of
pregnancy has recently been suggested by its correlation with gesta-
tional age and gender in a cohort of healthy preterm and term newborns
[11]. Notably, the higher LT levels were observed at gestational ages in
which CNS development was at its highest level in terms of brain
weight and volume, synaptogenesis, dendritic arborization and axonal
elongation [12–17]. However, the mechanisms through which LT may
participate in CNS development are not understood and LT correlations
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with consolidated neurobiomarkers of CNS development and damage
are also still lacking. This is true also for activin A, which is a growth
factor composed of two beta subunits belonging to the transforming
growth factor beta superfamily of dimeric proteins. Activin A, its re-
ceptors, and binding proteins are widely distributed throughout the
brain [18,19]. Among several activin A functions, in human and in
animal models, it has been shown that the protein plays a relevant role
in the common response to acute neuronal damage of various origins
(hypoxic/ischemic injury, mechanical irritation, and chemical damage)
and in the neuroprotection [20–22]. Elevated activin A levels in dif-
ferent biological ﬂuids (cerebrospinal, cord, peripheral blood, urine)
were observed at an earlier stage in fetuses/newborns complicated by
acute and chronic hypoxia, perinatal asphyxia and cerebral hemorrhage
[23–26].
Therefore, in the present study we aimed at investigating whether in
a cohort of healthy preterm and term infants LT assessment in arterial
cord blood correlated with activin A levels measured in the same
samples, thereby supporting its involvement in CNS development.
2. Materials and methods
The local Ethics Committees approved the study protocol and the
parents of the examined subjects gave informed consent.
We recruited 132 women with consecutive singleton physiological
pregnancies (82 at term and 50 preterm), whose deliveries were be-
tween 33 and 42 weeks of gestational age (wGA). Arterial cord blood
samples were taken from newborns at birth for standard laboratory
monitoring parameters, LT and activin A assessment.
GA was determined by clinical data and by ﬁrst trimester ultrasound
scan. Appropriate growth was deﬁned by the presence of ultra-
sonography signs (when biparietal diameter and abdominal cir-
cumference were between the 10th and the 90th centiles), according to
the normograms of Campbell and Thoms [27], and by postnatal con-
ﬁrmation of a birth weight (BW) between the 10th and 90th centiles
according to our population standards, corrected for the mother's
height, weight, parity and the sex of the newborn. Newborns were
classiﬁed as preterm when born< 37 wGA and as term when born>
37 wGA, with a BW ranging from the 10th to 90th centile according to
our population standards. In all cases, GA was determined by the last
menstrual period and conﬁrmed by a ﬁrst trimester ultrasound scan. At
birth, both term and preterm newborns showed a normal postnatal
neurologic outcome at the 7th day of age and at discharge from hospital
fulﬁlled all of the following criteria: no maternal illness; no signs of
fetal distress; pH > 7.2 in cord or venous blood; and Apgar
scores > 7 at 1 and 5 min. Exclusion criteria were: multiple preg-
nancies, intrauterine growth retardation, gestational hypertension,
diabetes and infections, fetal malformations, chromosomal abnormal-
ities, perinatal asphyxia and dystocia. At birth arterial cord blood
samples were collected, centrifuged at 2500g and stored at −80 °C for
LT and activin A measurement.
2.1. Neurological examination
Neurological examination was performed daily during hospitaliza-
tion. Neonatal neurological conditions were classiﬁed using a qualita-
tive approach, as described by Prechtl [28], assigning each infant to one
of three diagnostic groups: normal, suspect or abnormal. An infant was
considered to be abnormal when one or more of the following neuro-
logical syndromes were present: hyper- or hypokinesia, hyper- or hy-
potonia, hemisyndrome, apathy syndrome, hyperexcitability syndrome.
An infant was classiﬁed as suspect if, in absence of a deﬁned syndrome,
only isolated signs were present. On admission to the Neonatal In-
tensive Care Unit, all newborns routinely underwent an assessment of
clinical parameters (red blood cell count, venous blood pH, ion con-
centrations, plasma glucose level, arterial blood pressure), cerebral
ultrasound and neurological examination.
2.2. Lutein extraction and high performance liquid chromatography
(HPLC) analysis
We decided to investigate LT pattern of concentration in newborns
since it represents the most predominant carotenoid found in the CNS.
Thus, LT extraction and HPLC analysis were performed using analytical
conditions reported in our previous work [11]. Brieﬂy, an aliquot of
500 μL of serum was treated with 500 μL of ethanol (1% BHT) in order
to precipitate proteic pellet. Hydroalcoholic fraction and pellet were
separately extracted twice with 500 μL of hexane. Hexanic fractions,
containing serum carotenoids, were combined, evaporated under ni-
trogen and solubilized in 50 μL of chloroform before HPLC analysis.
Chromatographic separation of LT was performed on a LC-10 AD Shi-
madzu HPLC system equipped with binary pump and a column com-
partment, coupled to a UV-diode array detector. Separation was per-
formed on a Develosil 5 μm RP-AQUEUOUS C30, 250 × 4,6 mm
column (Phenomenex Torrance, CA, USA) using chromatographic
conditions previously reported [11].
Quantiﬁcation of LT was done by the external standard method
using a calibration curve built with LT as reference standard. The
lowest point of the calibration curve (LOD, limit of detection) was
0.017 nmol/mL.
2.3. Mass spectrometry equipment and condition
The identiﬁcation of LT was conﬁrmed by liquid chromatography
coupled to a tandem mass spectrometer (LC/MS/MS). The chromato-
graphic separation was performed by HPLC connected with two micro-
pumps 200 (Perkin Elmer, Carlsbad, CA, USA), using the same column
and the same chromatographic conditions described for HPLC analysis.
The API 3000 tandem mass spectrometer (API 3000, Applied Biosystem,
Waltham, MA, USA) equipped with an atmospheric pressure chemical
ionization (APCI) source was used for mass spectrometry analysis. The
optimum settings of the mass spectrometer were: probe temperature
500 °C, the nebulizer current 4 μA, declustering potential 45 V and fo-
cusing potential 300 V.
2.4. Activin A measurement
Activin A measurement was performed in duplicate using a speciﬁc
two-site enzyme immunoassay purchased from Serotec (Oxford,
Oxford, UK) as previously described [18]. The limit of detection for
activin A was 10 pg/mL, and intra- and inter-assay coeﬃcients of var-
iation were 2.5% and 3.0% respectively. The activin A assay has no
detectable cross-reaction with inhibin A, inhibin B, follistatin or activin
B. Activin A plates were read at 490 nm on an automated ELISA plate
reader.
2.5. Statistical analysis
Clinical data are reported as the mean and standard deviation (SD).
LT and activin A data are reported as median and interquartile centiles.
Statistical analysis was performed using XLStat-Pro v.7.2.5 (Addinsoft,
New York, USA). The results of neonatal monitoring parameters were
compared between groups by the two-sided Mann–Whitney U test and
by Kruskal–Wallis one-way ANOVA followed by the Dunn post-hoc test
when the data did not follow a Gaussian distribution. Comparisons
between proportions were performed with the Fisher exact test. Linear
regression analysis was performed for correlations between LT, activin
A and GA, respectively. A value of P < 0.05 was considered sig-
niﬁcant.
3. Results
Table 1 shows maternal and perinatal characteristics in the term and
preterm newborns.
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In particular, maternal age, delivery mode, gender, Apgar scores at
1st and 5th minutes, arterial cord blood pH, SaO2, neurological ex-
amination, cerebral ultrasound patterns and the incidence of cases with
a BW between the 10th and 90th centiles did not diﬀer (P > 0.05, for
all) in preterm and term groups. Moreover, at discharge from hospital,
no overt neurological syndrome was detectable in all infants admitted
to the study. As expected, wGA age and BW were signiﬁcantly lower
(P < 0.001, for both) in PN.
Laboratory and monitoring parameters (red blood cell count, ve-
nous blood pH, ion concentrations, plasma glucose level, arterial blood
pressure) were superimposable (P > 0.05, for all) in the two groups.
Activin A concentrations were measurable in all the samples col-
lected. The protein showed a pattern of concentration characterized by
higher levels in the early wGA (P < 0.01, for all) with a peak at 33–36
wGA (activin A median: 475.73 pg/mL; 25th–75th centile:
328.37–1076.07 pg/mL) and by a progressive decrease, with a dip at 42
wGA (activin A median: 130 pg/mL; 25th–75th centile: 120–240 pg/
mL). After sub-dividing for gender, activin A levels were found to be
higher (P < 0.01, for all) in the female study population and after sub-
grouping for preterm and term birth (Fig. 1, panel A).
LT concentrations were measurable in all the samples collected. LT
showed a pattern of concentration characterized by higher levels in the
early wGA (P < 0.01, for all) with a peak at 33‐36 wGA (LT median:
76.50 pmol/mL; 25th–75th centile: 65.86–135.95 pmol/mL), followed
by a progressive decrease in LT levels from 37 wGA onwards, with a dip
at 42 wGA (LT median: 52.27 pmol/mL; 25th–75th centile:
36.97–65.83 pmol/mL). LT correlated signiﬁcantly (P < 0.01) with
wGA at sampling (R = 0.31; P < 0.001).
LT levels after sub-dividing for gender were found to be higher
(P < 0.01, for all) in the female study population and after sub-
grouping for preterm and term birth (Fig. 1, panel B).
3.1. Lutein and activin A correlations
LT and activin A inversely correlated (R =−0.22; P = 0.017)
when the whole study population was considered (data not shown).
However, when divided for gender, we found that LT positively cor-
related with activin A both in whole male (R = 0.93; P < 0.001) and
Table 1
Perinatal characteristics in preterm and term newborns. Data are given as mean (SD).
Parameters Preterm (n = 50) Term (n = 82)
Maternal Age (y) 29 (4) 28 (5)
Mode of delivery, n (%)
Caesarean 27 (54) 20 (24.4)
Vaginal 23 (46) 62 (75.6)
GA (weeks) 34 (2) 39 (2)⁎
BW (g) 2675 (489) 3311 (501)⁎
Gender (male/female) 27/23 43/39
Apgar score > 7 n (%)
At 1 min 50 (100) 82 (100)
At 5 min 50 (100) 82 (100)
SaO2 (%) 96 ± 2 97 ± 2
Red blood cell count (106/mm3) 3.91 ± 0.1 3.9 ± 0.07
Hemoglobin (g/dL) 13.4 ± 0.03 13.6 ± 0.04
Hematocrit rate % 40.3 ± 0.4 41.1 ± 0.2
Venous blood pH 7.31 ± 0.01 7.36 ± 0.06
Partial venous CO2 pressure (mmHg) 42.6 ± 1.5 41.3 ± 1.5
Partial venous O2 pressure (mmHg) 39.1 ± 0.9 40.3 ± 0.9
Base excess −0.5 ± 0.2 −0.2 ± 1.1
Na+ (mmol/L) 139 ± 0.4 140 ± 0.5
K+ (mmol/L) 4.1 ± 0.1 4.1 ± 0.2
Ca++ (mmol/L) 1.13 ± 0.03 1.14 ± 0.03
Prechtl score at admission to NICU
(normal/total)
Normal 50 (50) 82 (82)
Suspect 0 (50) 0 (82)
Abnormal 0 (50) 0 (82)
Cerebral ultrasound (normal/total) 50 (50) 82 (82)
Abbreviations: Gestational age, GA; Birth-weight, BW; arterial oxygen saturation, SaO2;
carbon dioxide partial pressure, CO2; oxygen partial pressure, O2.
⁎ P < 0.05.
Fig. 1. Panel A. Activin A (pg/mL) arterial cord blood concentrations in whole studied
population (Tot) and when divided for gender (male: M; female: F) and sub-grouped for
preterm (PT) and term (T) births. Data are given as medians and 5th–95th centiles. Panel
B. Lutein (pmol/mL) arterial cord blood concentrations in studied population when di-
vided for gender and sub-grouped for preterm and term births. Data are given as medians
and 5th–95th centiles.
Fig. 2. Lutein (pmol/mL) correlations with activin A (pg/mL) in samples collected from
arterial cord blood of preterm, term male ( ) and female (Δ) newborns. There were
signiﬁcant positive correlations between lutein and activin A in male (R = 0.93;
P < 0.001) and female (R = 0.89; P < 0.001) groups.
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female (R = 0.89; P < 0.001) populations (Fig. 2). Of note, identical
correlations were found when sub-grouping for preterm (male:
R = 0.92; female: R = 0.97; P < 0.001, for both) and term (male:
R = 0.96; female: R = 0.75; P < 0.001, for both) (data not shown).
4. Discussion
There is growing evidence that the pathophysiological steps in-
volved in CNS development and damage are still not fully understood
and they are therefore of interest as a subject of investigation.
Technological improvements have made it possible to identify and as-
sess new neuro-biomarkers. This is especially true for new laboratory
procedures such as metabolomics, which can identify the roles and
activities of metabolites [10]. In this respect, several biomarkers have
recently been proposed and investigations are in progress for their va-
lidation in accordance with Food and Drugs Administration and Eur-
opean Medicine Association statements [29].
In the present study we showed that LT concentrations in the ar-
terial cord blood of healthy preterm and term newborns were gesta-
tional age- and gender-dependent and correlated with a well-estab-
lished marker of CNS development and damage, namely activin A
[21–26,29]. Moreover, activin A and LT patterns of concentration
showed higher levels in the early weeks of the third trimester of ge-
station (i.e. 33–36 weeks), starting to decrease from 37 weeks onwards
and reaching their dip at term.
The ﬁnding that LT is gestational age-dependent is not surprising; it
ﬁts previous observations and oﬀers additional support in the debate
concerning a putative trophic role for LT [8–11]. It is noteworthy, in
this respect, that LT levels were higher at 33–36 weeks, i.e. in the so-
called late preterm period, in parallel with higher activin A con-
centrations. This ﬁnding warrants further consideration bearing in
mind that at this stage CNS development is at its highest level in terms
of brain volume, weight and structure [12–15]. In particular, brain
volume and weight increase respectively to 35% and 37% of the total
amount during pregnancy, when myelinization and arborization pro-
cesses are at their maximum peaks [12–15]. These ﬁndings were further
corroborated by recent observations of CNS development and function
monitoring, in humans, by magnetic resonance imaging (MRI), neuro-
biomarker assessment in diﬀerent biological ﬂuids and non-invasive
techniques such as near infrared spectroscopy (NIRS) [15–17,29–31].
MRI provided evidence on the timing and duration of CNS development
at the stage of investigation [15]. Moreover, the assessment in biolo-
gical ﬂuids of consolidated neuro-biomarkers of CNS development and
function such as S100B protein and activin A were in agreement with
MRI patterns and with the biochemical, morphological and electro-
physiological maturation of the CNS [29–31]. In this regard, the me-
chanisms through which LT and activin A can both act as markers of
CNS development/damage are not fully understood and merit further
consideration. On the one hand trophic and protective roles for LT in
humans have been suggested by: i) its predominant localization in CNS
areas crucial for learning and memory [10], ii) its correlation with fatty
acids and lysophospholipids involved in cortical development and
folding [32–34], in oligodendrocyte maturation [35] and in in-
tracellular and cell-cell signalling; iii) the correlation with 1-octade-
canol, phosphate and NADH, metabolites associated with energy
pathways, supporting the notion that LT participates in myelination
during development as oligodendrocytes require extremely high meta-
bolic rates during peak myelination [34,35], and iv) the correlation
with the aminoacid neurotransmitters GABA and aspartate, involved in
the modulation of neuronal proliferation and maturation, neurite out-
growth and synapse formation and neurotransmission [36–39]. On the
other hand, activin A: i) shows an instructive neuronal eﬀect in cortical
and hippocampal neuronal progenitor cells, playing a relevant role in
their speciﬁcation towards a neuronal phenotype [18], ii) increases
survival of diﬀerentiated neurons [40]; iii) promotes neuron-re-
generation after hypoxic insults [18,30], iii) exaggerated releasing after
hypoxic insult as expression of increased neuro-protection and neuro-
regeneration processes [18,30,31], and iv) following hypoxia, corre-
lates with biochemical markers of oxidative stress, nucleated red blood
cell counts, hypoxanthine, xanthine, base deﬁcit levels, and pH [25].
Altogether, on the basis of the above ﬁndings it is possible to argue that
LT and activin A participate in a cascade of events modulating CNS
development and protecting it from damage. The possibility that LT and
activin A may be triggered by a hypoxic insult is thus consistent and,
together with their eﬀects on CNS development and damage, is a pro-
mising avenue of investigation.
Finally, NIRS studies in healthy infants have provided evidence that
in the late preterm period CNS pattern of development is characterized
by an improved oxygenation status and increased tissue function
[16,17]. Thus, it is reasonable to conclude that the pattern of con-
centration of LT in the third trimester of pregnancy, which is not sig-
niﬁcantly diﬀerent on that of other monitoring and well-established
biochemical markers, oﬀers additional support to its CNS trophic role.
In the present study, we also found that LT and activin A correlated
in a gender-dependent manner: these diﬀerences could be explained by
diﬀerent patterns of brain maturation in the two sexes and are in
agreement with previous observations comparing several fetal/neonatal
parameters such as growth, metabolic, biochemical and hormonal
patterns [16,18,29].
In humans and animal models it has been shown that there is a
developmental period for each species in which the CNS is more sen-
sitive to gonadal hormones eﬀects than at any other time. In mammals,
the heterogametic sex diﬀerentiation occurs as a result of gonadal
hormones releasing in the preterm period: the modulation and the
timing of estrogen and androgen releasing play a relevant role [41]. It
has been shown that fetus is continuously exposed to endogenous es-
trogen from placenta-maternal bloodstream trough a mechanism,
mediated by speciﬁc receptors, that protect fetus from estrogen side-
eﬀects and promote CNS growth. Conversely, androgen can act directly
on the CNS without mediated mechanisms [41]. In the CNS newborn,
the receptorial system is not static but change rapidly during and after
the perinatal period and the regional distribution of estrogen receptors
changes during development. These ﬁndings are supported by data in
animal model where estrogen receptors are the ﬁrst to increase, in
parallel with the onset of sensitivity of the CNS to the hormonal action,
leading to brain sexual diﬀerentiation [42]. Thus, CNS has a diﬀerent
gender answer to gonadal steroids in a time-dependent manner [42] in
whom interaction among gonads, adenohypophysis and inhibin-activin
family play a crucial role [43]. Altogether, it is reasonable to infer that
CNS development in the preterm period is signiﬁcantly precocious in
female [41]. The ﬁnding is also corroborated by results in clinical and
biochemical studies suggestive of an earlier CNS female maturation
[44–49]. However, further studies aimed at elucidating the mechanism
trough which LT and activin A participate in the cascade of events
leading to CNS development are so justiﬁed. The issue is of utmost
relevance bearing in mind that a later CNS development in male is
related with a higher incidence of prematurity and cerebral hemorrhage
as well as of multiorgan failure [47–49].
Finally, this study had a number of limitations. In particular, we
conducted a cross-sectional design and we did not record maternal diet
diary in order to know LT intake. Further investigations aimed at cor-
relating these two measures and potential implications to prenatal
dietary recommendations are therefore requested.
5. Conclusions
In conclusion, the present data showing a correlation between LT
and activin A support the notion of a neurotrophic role of LT and open
the way to further investigations correlating LT with well-established
biochemical markers of CNS development/damage.
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